Cargando…

Low-dose IL-2 mitigates glucocorticoid-induced Treg impairment and promotes improvement of SLE

Detalles Bibliográficos
Autores principales:	Zhou, Haotian, Zhao, Xiaozhen, Zhang, Ruijun, Miao, Miao, Pei, Wenwen, Li, Zijun, Li, Yimin, He, Jing, Li, Zhanguo, Sun, Xiaolin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068597/ https://www.ncbi.nlm.nih.gov/pubmed/37009820 http://dx.doi.org/10.1038/s41392-023-01350-6

Ejemplares similares

Therapeutic potential of targeting Tfr/Tfh cell balance by low-dose-IL-2 in active SLE: a post hoc analysis from a double-blind RCT study
por: Miao, Miao, et al.
Publicado: (2021)

Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2
por: Miao, Miao, et al.
Publicado: (2020)

Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients
por: Zhao, Chunmiao, et al.
Publicado: (2019)

Increased sIL-2Rα leads to obstruction of IL-2 biological function and Treg cells differentiation in SLE patients via binding to IL-2
por: Long, Dan, et al.
Publicado: (2022)

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
por: He, Jing, et al.
Publicado: (2020)

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

The association between diet and glucocorticoid treatment in patients with SLE
por: Lourdudoss, Cecilia, et al.
Publicado: (2016)

Double Negative B Cell Is Associated With Renal Impairment in Systemic Lupus Erythematosus and Acts as a Marker for Nephritis Remission
por: You, Xujie, et al.
Publicado: (2020)

Comparison of short interval and low dose (SILD) with high dose of cyclophosphamide in the susceptibility to infection in SLE: a multicentrereal-world study
por: Shao, Miao, et al.
Publicado: (2022)

Treg/IL-17 Ratio and Treg Differentiation in Patients with COPD
por: Jin, Yang, et al.
Publicado: (2014)

Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial
por: Zhang, Xiaoying, et al.
Publicado: (2022)

Modification of Intestinal Microbiota Dysbiosis by Low-Dose Interleukin-2 in Dermatomyositis: A Post Hoc Analysis From a Clinical Trial Study
por: Zhufeng, Yunzhi, et al.
Publicado: (2022)

Treatment of Active Idiopathic Inflammatory Myopathies by Low-Dose Interleukin-2: A Prospective Cohort Pilot Study
por: Miao, Miao, et al.
Publicado: (2021)

Tumors recycle glucocorticoids to drive Treg-mediated immunosuppression
por: Swatler, Julian, et al.
Publicado: (2023)

Low-dose IL-2 therapy invigorates CD8(+) T cells for viral control in systemic lupus erythematosus
por: Zhou, Pengcheng, et al.
Publicado: (2021)

Short-term assessment of BCR repertoires of SLE patients after high dose glucocorticoid therapy with high-throughput sequencing
por: Shi, Bin, et al.
Publicado: (2016)

IL-10 and TNFα Genotypes in SLE
por: López, Patricia, et al.
Publicado: (2010)

Impaired Differentiation of Highly Proliferative ICOS(+)-Tregs Is Involved in the Transition from Low to High Disease Activity in Systemic Lupus Erythematosus (SLE) Patients
por: Kälble, Florian, et al.
Publicado: (2021)

Galangin mitigates glucocorticoid-induced osteoporosis by activating autophagy of BMSCs via triggering the PKA/CREB signaling pathway: Galangin mitigates glucocorticoid-induced osteoporosis
por: Zeng, Chenying, et al.
Publicado: (2023)

Differential Effects of IL-12 on Tregs and Non-Treg T Cells: Roles of IFN-γ, IL-2 and IL-2R
por: Zhao, Jingxian, et al.
Publicado: (2012)

Dense mapping of IL18 shows no association in SLE
por: Guerra, Sandra G., et al.
Publicado: (2011)

Interleukin-1β (IL-1β) & IL-4 gene polymorphisms in patients with systemic lupus erythematosus (SLE) & their association with susceptibility to SLE
por: Mohammadoo-khorasani, Milad, et al.
Publicado: (2016)

Single nucleotide polymorphisms of HSP90AA1 gene influence response of SLE patients to glucocorticoids treatment
por: Zou, Yan-Feng, et al.
Publicado: (2016)

Low Dose Interleukin-2 Ameliorates Sjögren’s Syndrome in a Murine Model
por: Wang, Yifan, et al.
Publicado: (2022)

HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2 in Humanized Mice
por: Tyagi, Rajeev K., et al.
Publicado: (2021)

Vitamin A Impairs the Reprogramming of Tregs into IL-17-Producing Cells during Intestinal Inflammation
por: Tejón, Gabriela, et al.
Publicado: (2015)

IL-17C Mitigates Murine Acute Graft-vs.-Host Disease by Promoting Intestinal Barrier Functions and Treg Differentiation
por: Gong, Huanle, et al.
Publicado: (2018)

Natural Treg and role of IL-2 in lupus
por: Riemekasten, Gabriela, et al.
Publicado: (2011)

IL-2-based approaches to Treg enhancement
por: Harris, Ffion, et al.
Publicado: (2022)

Tumors produce glucocorticoids by metabolite recycling, not synthesis, and activate Tregs to promote growth
por: Taves, Matthew D., et al.
Publicado: (2023)

Impaired activation of STAT5 upon IL-2 stimulation in Tregs and elevated sIL-2R in Sjögren’s syndrome
por: Keindl, Magdalena, et al.
Publicado: (2022)

BTLA Expression and Function Are Impaired on SLE B Cells
por: Wiedemann, Annika, et al.
Publicado: (2021)

A Treg-Selective IL-2 Mutein Prevents the Formation of Factor VIII Inhibitors in Hemophilia Mice Treated With Factor VIII Gene Therapy
por: Chen, Alex C., et al.
Publicado: (2020)

IL-2 Inhibition of Th17 Generation Rather Than Induction of Treg Cells Is Impaired in Primary Sjögren’s Syndrome Patients
por: Luo, Jing, et al.
Publicado: (2018)

The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes
por: Dong, Shen, et al.
Publicado: (2021)

Comparison of the deep immune profiling of B cell subsets between healthy adults and Sjögren’s syndrome
por: Feng, Ruiling, et al.
Publicado: (2022)

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
por: Nakai, Takehiro, et al.
Publicado: (2022)

Increased Interleukin-17F is Associated with Elevated Autoantibody Levels and More Clinically Relevant Than Interleukin-17A in Primary Sjögren's Syndrome
por: Gan, Yuzhou, et al.
Publicado: (2017)

Reduced CCR6(+)IL-17A(+)Treg Cells in Blood and CCR6-Dependent Accumulation of IL-17A(+)Treg Cells in Lungs of Patients With Allergic Asthma
por: Shen, Xiaokun, et al.
Publicado: (2021)

Case report for recurrent and new-onset SLE patients treated by high-dose glucocorticoid therapy: Characteristics of peripheral TCR beta chain CDR3 repertoires
por: Yu, Jiang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hgd6ahdsalhj915610qinl5gim